沙美特罗替卡松对稳定期中重度慢性阻塞性肺疾病患者疗效探究

Efficacy of salmeterol and fluticasone propionate powder for inhalation in patients with stable moderate and severe chronic obstructive pulmonary disease

目的 探究沙美特罗替卡松（50/500 μg）干粉吸人剂对稳定期慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）患者的疗效.方法 65例稳定期中重度COPD患者随机分为对照组和治疗组,两组戒烟、氧疗、营养支持、肺功能康复等基础治疗措施相同.对照组给予沙丁胺醇、异丙托溴胺气雾剂吸入治疗;治疗组给予沙美特罗替卡松干粉吸入剂治疗,疗程12个月.结果 治疗组患者治疗2个月后肺功能明显改善,对照组无改善,两者比较有明显差异;治疗组患者12个月后肺功能虽下降,但下降速率较对照组减慢;治疗组急性加重次数较对照组减少.结论 在COPD稳定期患者应用沙美特罗替卡松,早期可改善COPD患者肺功能,长期可降低肺功能下降速率并减少COPD急性加重次数.

Objective To investigate the effects of treatment using salmeterol and fluticasone propionate powder inhalation （50/500μg） on patients with stable chronic obstructive pulmonary disease （COPD）. Methods 65 patients with stable moderate and severe COPD after hospital discharge were randomly divided into treatment and control groups. Two groups of foundation remedial measures and so on no-smoking,oxygen treatment,nutrition supports, lung function recovery are same. The control group was given salbutamol inhaler ipratropiutn bromide. The treatment group was given salmeterol and fluticasone propionate powder for inhalation. The treatment course is 12 months. Results The treatment group patients treat for 2 months the lung function distinct improvement. The control group do not have the improvement, both comparison has the obvious difference. Although the treatment group patient 12 months the lung function drops,but the drop speed compares the control group slow-down. The treatment group acute aggravation number of times compares the control group to reduce. Conclusions Using salmeterol and fluticasone propionate powder inhalation on patients with stable COPD,the early time may improve the COPD patient lung function,may reduce the lung function drop speed and reduce the COPD acute aggravation number of times for a long time.